Naureen Quibria
Stock Analyst at Capital One
(n/a)
# 4,781
Out of 4,786 analysts
11
Total ratings
9.09%
Success rate
-45.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Naureen Quibria
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Initiates: Overweight | $25 | $2.30 | +986.96% | 1 | Aug 29, 2024 | |
| IMMP Immutep | Initiates: Overweight | $10 | $1.86 | +437.63% | 1 | May 17, 2024 | |
| ERAS Erasca | Initiates: Overweight | $8 | $1.52 | +426.32% | 1 | Mar 11, 2024 | |
| CARM Carisma Therapeutics | Initiates: Overweight | $10 | $0.33 | +2,930.30% | 1 | Oct 3, 2023 | |
| IMCR Immunocore Holdings | Initiates: Overweight | $84 | $29.58 | +183.98% | 1 | Aug 16, 2023 | |
| DAWN Day One Biopharmaceuticals | Initiates: Overweight | $40 | $8.07 | +395.66% | 1 | Feb 8, 2023 | |
| FENC Fennec Pharmaceuticals | Initiates: Overweight | $11 | $6.50 | +69.23% | 1 | Sep 7, 2022 | |
| CMRX Chimerix | Initiates: Overweight | $7 | $8.50 | -17.65% | 2 | Sep 7, 2022 | |
| GNTA Genenta Science | Initiates: Buy | $21 | $3.97 | +428.97% | 1 | Jan 13, 2022 | |
| KZIA Kazia Therapeutics | Initiates: Buy | $180 | $0.88 | +20,352.22% | 1 | Oct 14, 2021 |
Biomea Fusion
Aug 29, 2024
Initiates: Overweight
Price Target: $25
Current: $2.30
Upside: +986.96%
Immutep
May 17, 2024
Initiates: Overweight
Price Target: $10
Current: $1.86
Upside: +437.63%
Erasca
Mar 11, 2024
Initiates: Overweight
Price Target: $8
Current: $1.52
Upside: +426.32%
Carisma Therapeutics
Oct 3, 2023
Initiates: Overweight
Price Target: $10
Current: $0.33
Upside: +2,930.30%
Immunocore Holdings
Aug 16, 2023
Initiates: Overweight
Price Target: $84
Current: $29.58
Upside: +183.98%
Day One Biopharmaceuticals
Feb 8, 2023
Initiates: Overweight
Price Target: $40
Current: $8.07
Upside: +395.66%
Fennec Pharmaceuticals
Sep 7, 2022
Initiates: Overweight
Price Target: $11
Current: $6.50
Upside: +69.23%
Chimerix
Sep 7, 2022
Initiates: Overweight
Price Target: $7
Current: $8.50
Upside: -17.65%
Genenta Science
Jan 13, 2022
Initiates: Buy
Price Target: $21
Current: $3.97
Upside: +428.97%
Kazia Therapeutics
Oct 14, 2021
Initiates: Buy
Price Target: $180
Current: $0.88
Upside: +20,352.22%